At first, Bastard and colleagues identified autoantibodies against IFN-α or IFN-ω in ~13.6% of patients with critical COVID-19, with age-related prevalence (21% in patients >80 years), while anti-IFN-β antibodies were found in ~1.3% severe COVID-19 patients, independently from age. Here, IFNA1 is linked to COVID-19.